Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Starts China Trial of PD-1/TIGIT Bispecific for Solid Tumors

publication date: Jul 26, 2021

Suzhou Innovent Bio started a China Phase I trial of an anti-PD-1/TIGIT bispecific antibody in advanced malignant tumors, especially GI cancers. Innovent said preclinical studies of IBI321 showed it retains the activity of a PD-1 inhibitor while suppressing TIGIT to enhance anti-cancer efficacy. TIGIT is an immune checkpoint receptor that plays a role in tumor immune surveillance. IBI321 was discovered through a collaboration between Innovent and Eli Lilly, but is being developed in China by Innovent. The Phase Ia study will evaluate dosing of IBI321 in several solid tumors. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China